While the vaccine was shown to reduce the risk of babies contracting RSV, they stopped enrollment in the trial early due to the safety concerns, researchers recount in an analysis published March 14 in the New England Journal of Medicine.
The defunct phase 3 trial enrolled 5,328 pregnant women between 18 and 49 years of age and 5,233 infants between November 2020 to February 2022, when the trial was halted.
“The results of this trial, in which enrollment was stopped early because of safety concerns, suggest that the risks of any and severe medically assessed RSV-associated lower respiratory tract disease among infants were lower with the candidate maternal RSV vaccine than with placebo but that the risk of preterm birth was higher with the candidate vaccine,” the authors wrote.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
